Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9H2C2
UPID:
ARV1_HUMAN
Alternative names:
-
Alternative UPACC:
Q9H2C2; A8KAI4; Q5VSN7; Q5VSN8; Q5VSN9; Q5VSP0; Q5VSP2; Q9H2H2; Q9H5V6; Q9UFF5
Background:
Protein ARV1 plays a crucial role in mediating endoplasmic reticulum (ER) cholesterol and bile acid homeostasis. It is involved in sterol transport out of the ER, ensuring proper distribution into plasma membranes. This protein's function is pivotal in maintaining cellular lipid balance, a fundamental aspect of cell biology and metabolism.
Therapeutic significance:
Protein ARV1 is linked to Developmental and Epileptic Encephalopathy 38 (DEE38), a severe early-onset epilepsy with neurodevelopmental impairment. Understanding the role of Protein ARV1 could open doors to potential therapeutic strategies for treating DEE38, offering hope for patients and families affected by this devastating condition.